Introduction
tumor, cancer, intrahepatic tumor, BCLC, primary liver cancer, HCC
PRIMARY LIVER CANCER, CANCER, TUMOR, HEPATOCELLULAR CARCINOMA
Worldwide, primary liver cancer ranks as the sixth most frequent cancer diagnosis and stands third in terms of cancer-related mortality, with hepatocellular carcinoma (HCC) accounting for 75–80% of these primary liver cancer cases.The union of PD-(L)1 inhibitors with agents targeting VEGF has marked a pivotal shift in HCC management, as evidenced initially in the IMbrave150 study.Hepatic arterial infusion chemotherapy (HAIC) using a combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) is effective in decreasing the intrahepatic tumor burden, as it allows for the targeted delivery of chemotherapy drugs to the arteries supplying the tumor.With all above mentioned, it is hypothesized that camrelizumab and apatinib in combination with HAIC may further improve outcomes. Consequently, this investigation was designed to evaluate the therapeutic benefit of camrelizumab and apatinib when used alongside HAIC-FOLFOX in HCC patients at BCLC stage C.